Liminal BioSciences (NASDAQ:LMNL – Get Free Report) and Oxurion (OTCMKTS:TBGNF – Get Free Report) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership. Institutional & Insider Ownership 0.7% of Liminal BioSciences shares […]
Liminal BioSciences Inc. (NASDAQ:LMNL – Get Free Report) was the target of a significant growth in short interest in July. As of July 15th, there was short interest totalling 34,300 shares, a growth of 19.9% from the June 30th total of 28,600 shares. Approximately 4.1% of the company’s stock are sold short. Based on an […]
Liminal BioSciences (NASDAQ:LMNL – Get Free Report) and Histogen (NASDAQ:HSTO – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, analyst recommendations and valuation. Valuation & Earnings This table compares Liminal BioSciences […]
Liminal BioSciences Inc. (NASDAQ:LMNL – Get Rating) was the target of a significant growth in short interest in the month of April. As of April 15th, there was short interest totalling 96,300 shares, a growth of 4,968.4% from the March 31st total of 1,900 shares. Based on an average trading volume of 150,300 shares, the […]
Liminal BioSciences (NASDAQ:LMNL – Get Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Thursday, Zacks.com reports. According to Zacks, “Liminal BioSciences Inc. is a biotechnology company. It engages in discovering, developing and commercializing novel small molecule compounds for respiratory, liver and renal diseases. […]